<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H9D334C15907246919E38D755E40BB4BE" key="H" public-private="public"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>115 HR 1409 IH: Cancer Drug Parity Act of 2017</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2017-03-07</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">115th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 1409</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20170307">March 7, 2017</action-date><action-desc><sponsor name-id="L000567">Mr. Lance</sponsor> (for himself, <cosponsor name-id="H001038">Mr. Higgins of New York</cosponsor>, <cosponsor name-id="H001045">Mr. Harper</cosponsor>, <cosponsor name-id="F000454">Mr. Foster</cosponsor>, <cosponsor name-id="S000250">Mr. Sessions</cosponsor>, <cosponsor name-id="G000559">Mr. Garamendi</cosponsor>, <cosponsor name-id="C000984">Mr. Cummings</cosponsor>, <cosponsor name-id="W000804">Mr. Wittman</cosponsor>, <cosponsor name-id="R000577">Mr. Ryan of Ohio</cosponsor>, <cosponsor name-id="P000592">Mr. Poe of Texas</cosponsor>, <cosponsor name-id="C001101">Ms. Clark of Massachusetts</cosponsor>, <cosponsor name-id="P000597">Ms. Pingree</cosponsor>, <cosponsor name-id="B001243">Mrs. Blackburn</cosponsor>, <cosponsor name-id="K000210">Mr. King of New York</cosponsor>, <cosponsor name-id="C001105">Mrs. Comstock</cosponsor>, <cosponsor name-id="K000380">Mr. Kildee</cosponsor>, <cosponsor name-id="D000625">Mr. Donovan</cosponsor>, <cosponsor name-id="C001103">Mr. Carter of Georgia</cosponsor>, <cosponsor name-id="D000191">Mr. DeFazio</cosponsor>, <cosponsor name-id="G000558">Mr. Guthrie</cosponsor>, <cosponsor name-id="P000607">Mr. Pocan</cosponsor>, <cosponsor name-id="L000576">Mr. Long</cosponsor>, <cosponsor name-id="S001193">Mr. Swalwell of California</cosponsor>, <cosponsor name-id="F000461">Mr. Flores</cosponsor>, <cosponsor name-id="M001185">Mr. Sean Patrick Maloney of New York</cosponsor>, <cosponsor name-id="M001151">Mr. Murphy of Pennsylvania</cosponsor>, <cosponsor name-id="W000797">Ms. Wasserman Schultz</cosponsor>, <cosponsor name-id="L000566">Mr. Latta</cosponsor>, <cosponsor name-id="M001193">Mr. MacArthur</cosponsor>, and <cosponsor name-id="K000381">Mr. Kilmer</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend the Public Health Service Act to require group and individual health insurance coverage
			 and group health plans to provide for cost sharing for oral anticancer
			 drugs on terms no less favorable than the cost sharing provided for
			 anticancer medications administered by a health care provider.</official-title></form>
	<legis-body id="HDB17EA5EA5054EEBA37F712BF5ABCCE9" style="OLC">
 <section id="HDBA8797D9DF24015AD829E9458413B57" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Cancer Drug Parity Act of 2017</short-title></quote>.</text> </section><section id="H357A58D0C63841529C33E21D170778A8"><enum>2.</enum><header>Parity in cost sharing for oral anticancer drugs</header> <subsection display-inline="no-display-inline" id="H3058879F500844EE970AFC293E4BC040"><enum>(a)</enum><header>Requirement</header> <paragraph commented="no" display-inline="no-display-inline" id="H2A191E8121BC40178A2CBD784AFE64BE"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">Section 2719A of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300gg-19a">42 U.S.C. 300gg–19a</external-xref>) is amended by adding at the end the following new subsection:</text>
					<quoted-block id="H7588F7FDEFEE4C1191FF1D071AB67939" style="OLC">
						<subsection id="H39416B0014BE4545B013425A7499CB43"><enum>(e)</enum><header>Parity in cost sharing for oral anticancer drugs</header>
 <paragraph display-inline="no-display-inline" id="H64666FADBB544213A1FA5ED5D35DEAC0"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">Subject to paragraph (2), a group health plan, and a health insurance issuer offering group or individual health insurance coverage, that provides benefits with respect to anticancer medications administered by a health care provider shall provide that any cost sharing for prescribed, patient-administered anticancer medications that are used to kill, slow, or prevent the growth of cancerous cells and that have been approved by the Food and Drug Administration is no less favorable than the cost sharing for anticancer medications that is intravenously administered or injected by a health care provider.</text>
 </paragraph><paragraph commented="no" id="HF7F5A8CB27474FB3B6406A54E0DCA603"><enum>(2)</enum><header>Limitation</header><text>Paragraph (1) shall only apply to an anticancer medication that is prescribed based on a finding by the treating physician that the medication—</text>
 <subparagraph commented="no" id="HDB2169F3188440DFB013295B317615C2"><enum>(A)</enum><text>is medically necessary for the purpose of killing, slowing, or preventing the growth of cancerous cells; or</text>
 </subparagraph><subparagraph commented="no" id="HF30E3F3321C34FAE949BF929C21A7C75"><enum>(B)</enum><text>is clinically appropriate in terms of type, frequency, extent site, and duration.</text> </subparagraph></paragraph><paragraph commented="no" id="HD012358D949B4611A49D9F692C0417A8"><enum>(3)</enum><header>Restriction on certain changes</header><text display-inline="yes-display-inline">A group health plan or health insurance issuer may not, in order to comply with the requirement of paragraph (1), make changes to benefits or replace existing benefits with new benefits under the plan or health insurance coverage designed to have the effect of—</text>
 <subparagraph commented="no" id="H4C806B9BDBBB4FD19B6A59A1D49F7656"><enum>(A)</enum><text>imposing an increase in out-of-pocket costs with respect to anticancer medications;</text> </subparagraph><subparagraph commented="no" id="H92463DE093214AF9B5777E9B821E8C3A"><enum>(B)</enum><text display-inline="yes-display-inline">reclassifying benefits with respect to anticancer medications in a way that would increase such costs; or</text>
 </subparagraph><subparagraph id="H3794B7F1774B42E0B163A471D5F7E066"><enum>(C)</enum><text>applying more restrictive limitations on prescribed orally administered anticancer medications than on intravenously administered or injected anticancer medications.</text>
 </subparagraph></paragraph><paragraph id="HF8B986FE90644413B00B51A717B192CE"><enum>(4)</enum><header>Construction</header><text>Nothing in this subsection shall be construed—</text> <subparagraph id="HA75FDCA5F1D8489AA45CBC32682911A9"><enum>(A)</enum><text display-inline="yes-display-inline">to require the use of orally administered anticancer medications as a replacement for other anticancer medications;</text>
 </subparagraph><subparagraph id="HB8A71C14304A410DADFA3559D3AEF51A"><enum>(B)</enum><text>to prohibit a group health plan or health insurance issuer from requiring prior authorization or imposing other appropriate utilization controls in approving coverage for any chemotherapy; or</text>
 </subparagraph><subparagraph id="HACE576FC041344B59B6CFB8593AD2E4C"><enum>(C)</enum><text>to supersede a State law that provides greater protections with respect to the coverage with respect to orally administered anticancer medications than is provided under this subsection.</text>
 </subparagraph></paragraph><paragraph id="H2568F16D89214AADB4FCC7F23FC89FC0"><enum>(5)</enum><header>Cost sharing defined</header><text>In this subsection, the term <term>cost sharing</term> includes a deductible, coinsurance, copayment, and any maximum limitation on the application of such a deductible, coinsurance, copayment, and similar out-of-pocket expenses.</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
 </paragraph><paragraph id="HF6263E111CD945C2B23C0C7CFF15D146"><enum>(2)</enum><header>Conforming amendment</header><text>Section 2724(c) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300gg-23">42 U.S.C. 300gg–23(c)</external-xref>) is amended by striking <quote>section 2704</quote> and inserting <quote>sections 2719A, 2725, and 2726</quote>.</text> </paragraph></subsection><subsection display-inline="no-display-inline" id="HB6D075A7AEBE42BFA86FAA945617FC5B"><enum>(b)</enum><header>Clarifying amendment regarding application to grandfathered plans</header><text display-inline="yes-display-inline">Section 1251(a)(4)(A) of the Patient Protection and Affordable Care Act (<external-xref legal-doc="usc" parsable-cite="usc/42/18011">42 U.S.C. 18011(a)(4)(A)</external-xref>) is amended by adding at the end the following new clause:</text>
				<quoted-block display-inline="no-display-inline" id="H06524B03E3824B1589BC94BC83AE9643" style="OLC">
 <clause id="HFD9F2FEA48344FD2B915BD64F2975E4A"><enum>(v)</enum><text display-inline="yes-display-inline">Section 2719A(e) (relating to cost sharing for oral anticancer drugs).</text></clause><after-quoted-block>.</after-quoted-block></quoted-block> </subsection><subsection id="HC0690EDD4A354BC8BCE04B16241D6886"><enum>(c)</enum><header>Effective date</header><text display-inline="yes-display-inline">The amendments made by this section shall apply with respect to group health plans for plan years beginning on or after January 1, 2018, and with respect to health insurance coverage offered, sold, issued, renewed, in effect, or operated in the individual or group market on or after such date.</text>
			</subsection></section></legis-body></bill>


